Open original FDA record ↗Recall record
- FDA identifier
- Z-0383-2019
- Company in FDA record
- Qiagen Sciences LLC
- FDA record creation date
- Nov 3, 2018
- First observed by MedTech Watch
- Nov 16, 2026
- Latest observed content change
- Nov 16, 2026
- Recall classification
- Class II
Reason stated in the source
An issue with the power branching printed circuit board (PCB) on the instrument that has the potential to trigger a heater malfunction was discovered. If this failure were to occur, nucleic acid extractions could be compromised and extractions need to be repeated. This could cause a delay in obtaining results from downstream applications.
Source facts
- Action
- The firm sent an Urgent Notice of Product Field Action letters dated July 23, 2018 to customers. The letter identified the affected product, problem and actions to be taken by the customer/user/commercial partner in order to assure that your instrument is currently functioning properly. Customers were asked to complete and sign the included Acknowledgement of Receipt form and either email it to QIAGEN Technical Service at Techservice-eu@qiagen.com or fax it to +49 (0)2103-29-22400. For questions contact your local QIAGEN Technical Services Department.
- Initiated
- 2018-07-23
- Root cause
- Nonconforming Material/Component
- Terminated
- 2020-06-05
- Distribution
- Worldwide Distribution - US Nationwide in the states of: AZ, CA, FL, GA, IA, ID, IL, MA, MD, MI, MN, NE, NJ, NY, NV, OH, PA, PR, SD, VA, and WA. The products were distributed to the following foreign countries: Alger, Argentina, Australia, Austria, Canada, China, Dubai, Egypt, France, Germany, Greece, Hungary, India, Italy, Japan, Jordan, Korea, Latvia, Mexico, Morocco, Norway, Qatar, Russia, Saudi Arabia, Singapore, Slovenia, Spain, Sweden, Switzerland, Tunisia, Turkey, UK.
- Recall number
- Z-0383-2019
- Recall status
- Terminated
- CDRH record ID
- 166755
- FDA record created
- 2018-11-03
- Recall event number
- 80862